治疗慢性乙型肝炎的AASLD指南

StephenW

Hepatology. 2015 Nov 13. doi: 10.1002/hep.28156. [Epub ahead of print]
AASLD guidelines for treatment of chronic hepatitis B.Terrault NA1, Bzowej NH2, Chang KM3, Hwang JP4, Jonas MM5, Murad MH6.
Author information

• 1University of California San Francisco, San Francisco, CA.
• 2Ochsner Medical Center, New Orleans, LA.
• 3Corporal Michael J. Crescenz VA Medical Center & University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
• 4The University of Texas MD Anderson Cancer Center, Houston, TX.
• 5Boston Children's Hospital, Harvard Medical School, Boston, MA.
• 6Mayo Clinic, Rochester, MN.
  

肝病。2015年13月DOI：10.1002/ hep.28156。 [打印EPUB提前]
治疗慢性乙型肝炎的AASLD指南
Terrault NA1，Bzowej NH2，长安KM3，黄某JP4，乔纳斯MM5，穆拉德MH6。
作者信息

    加州大学旧金山1University，加利福尼亚州旧金山
    2Ochsner医学中心，新奥尔良，洛杉矶。
    3Corporal迈克尔J. Crescenz VA医学中心与医药，宾夕法尼亚州费城，宾夕法尼亚佩雷尔曼学院。
    得克萨斯大学MD安德森癌症中心，休斯敦，得克萨斯州4The大学。
    5Boston儿童医院，哈佛大学医学院，马萨诸塞州波士顿。
    6Mayo诊所，明尼苏达州罗彻斯特市。

StephenW

From Christine Kukka:

The American Assoc. for the Study of Liver Disease (AASLD), which writes the
treatment guidelines for hepatitis B, has just updated treatment guidelines
for HBV. This is the first time they've done this in several years. The new
guidelines are at: http://cirrus.mail-list.com/hepatitis-b/67108567.html
The experts took up the following questions and issues when they wrote these
new guidelines (see below). I haven't read them yet but everyone should
review them to see if anything applies to their condition, and if they should
raise the new treatment recommendations with their doctors. Good luck, Chris
K

1. Should adults with immune active CHB be
treated with antiviral therapy to decrease liver-related
complications?
2. Should adults with immune-tolerant infection be
treated with antiviral therapy to decrease liver-related
complications?
3. Should antiviral therapy be discontinued in hepatitis
B e antigen (HBeAg)-positive persons who have
developed HBeAg seroconversion on therapy?
4. Should antiviral therapy be discontinued in persons
with HBeAg-negative infection with sustained
HBV DNA suppression on therapy?
5. In HBV-monoinfected persons, does entecavir therapy,
when compared to tenofovir therapy, have a
different impact on renal and bone health?
6. Is there a benefit to adding a second antiviral
agent in persons with persistent low levels of viremia
while being treated with either tenofovir or
entecavir?
7. Should persons with compensated cirrhosis and low
levels of viremia be treated with antiviral agents?
8. Should pregnant women who are hepatitis B surface
antigen (HBsAg) positive with high viral
load receive antiviral treatment in the third trimester
to prevent perinatal transmission of HBV?
9. Should children with HBeAg-positive CHB be
treated with antiviral therapy to decrease liverrelated
complications?

StephenW

从 Christine Kukka：

美国协会。肝脏疾病的研究（AASLD），其中写
乙肝治疗指南，刚刚更新的治疗指南
乙肝病毒。这是他们第一次在几年做到了这一点。新的
指引在：http://cirrus.mail-list.com/hepatitis-b/67108567.html
专家们讨论了以下问题和问题时，他们写这些
新准则（见下文）。我没有看过他们还没有，但每个人都应该
审查他们是否有任何适用于自己的病情，以及他们是否应该
与他们的医生抬高新的治疗建议。祝你好运，克里斯
ķ

1.如果成人的免疫活性CHB是
抗病毒疗法治疗，以减少肝脏相关
并发症？
2.应成年人免疫耐受感染会
抗病毒疗法治疗，以减少肝脏相关
并发症？
3.如果抗病毒治疗肝炎停产
e抗原（HBeAg）阳性谁拥有阳性者
发达的HBeAg血清转换的治疗？
4.如抗病毒治疗在人停产
HBeAg阴性感染持续
HBV DNA抑制的治疗？
5.在HBV-monoinfected人，确实恩替卡韦治疗，
相比于替诺福韦治疗，有
对肾脏和骨骼健康的影响不同？
6.是否有利于增加第二抗病毒药
代理与病毒血症持续低水平人
同时用替诺福韦或治疗
恩替卡韦？
7.如果人有代偿性肝硬化，低
病毒血症水平与抗病毒药物进行治疗？
8.如果孕妇谁是乙肝表面
抗原（HBsAg）高病毒阳性
负载接受抗病毒治疗在孕晚期
防止乙肝病毒母婴传播？
9.如果孩子HBeAg阳性慢性乙型肝炎是
抗病毒疗法治疗，以减少liverrelated
并发症？